| Website | celatorpharma.com |
| Category | BioTech |
| Phone | (609) 243-0123 |
| Employees |
| TOTAL | $20M |
| VENTURE FUNDING TOTAL | $20M |
| Series D, 9/10 Thomas, McNerney & Partners Domain Associates Ventures West Quaker BioVentures TL Ventures GrowthWorks Capital BDC Venture Capital | $20M |
Celator Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies to treat cancer. The company focuses on CombiPlex, a drug ratio technology platform that enables to the development of combination therapies. Its products include CPX-1 (Irinotecan HCI-Floxuridine), a treatment for colorectal cancer; and CPX-351 (Cytarabine-Daunorubicin), a treatment for acute myeloid leukemia (AML). Celator Pharmaceuticals, Inc. was formerly known as Celator Technologies, Inc. The company was founded in 2000 and is headquartered in Princeton, New Jersey.
